RCT | Rituximab and MMF combo improves lung function vs. MMF in interstitial lung disease with NSIP pattern, but may increase infection risk

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial – European Respiratory Journal (link to abstract – $ for full-text)

Commentary on Twitter

ERJ: Rituximab plus MMF is associated with benefits in lung function and progression-free survival compared with MMF plus placebo after 24 weeks of treatment. The safety profile of rituximab plus MMF was similar to that of MMF plus placebo. https://t.co/Mv0IuzLljz pic.twitter.com/1igrt6uDK4

— ERS publications (@ERSpublications) June 11, 2023